Check out the SWSLHD Research News LibGuide!
We have new resources in the Library. Come and check them out!
Welcome to the Grand Rounds Further Reading List, Gastroenterology edition, brought to you by the Clinical Library, on Level 4, next to the Auditorium.
This library guide is to help support you in your professional development. Please give us feedback so we can improve this list in the future.
Some sections are under construction and will be ready later in the year. If you are presenting at a later Grand Rounds, please contact lynne.roberts3@health.nsw.gov.au and tell us about the content of your paper so we can add appropriate resources to the list for when you present. your paper.
If you have any questions, please contact the Clinical Library on 9722 8250 or email SWSLHD-BankstownLibrary@health.nsw.gov.au or visit us Monday to Fridays, 8.30am - 5.00pm.
“MASLD is the new NAFLD”
All journal articles are available via CIAP, or by request from the Clinical Library, via our online request form.
Bae, J. C. (2024). "No More NAFLD: The Term Is Now MASLD." enm 39(1): 92-94: http://dx.doi.org/10.3803/EnM.2024.103
http://www.e-sciencecentral.org/articles/?scid=1516086436 PDF AT URL.
Chen, L., et al. (2024). "Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD." Journal of Hepatology 80(2): e64-e66: https://doi.org/10.1016/j.jhep.2023.08.021 PDF AT URL.
He, L., et al. (2024). "Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes." Journal of Hepatology 80(2): e85-e87: https://doi.org/10.1016/j.jhep.2023.09.035 PDF AT LINK.
Lu, Z., et al. (2024). "The transition from NAFLD to MASLD and its impact on clinical practice and outcomes." Journal of Hepatology 81(4): e155-e156: https://doi.org/10.1016/j.jhep.2024.02.021 FULL TEXT AT URL.
Perazzo, H., et al. (2024). "Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort." Journal of Hepatology 80(2): e72-e74: https://doi.org/10.1016/j.jhep.2023.08.025 PDF AT LINK.
Ramírez-Mejía, M. M. and N. Méndez-Sánchez (2023). "What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications." Current Hepatology Reports 22(4): 221-227: https://doi.org/10.1007/s11901-023-00620-9
PDF AT LINK.
This review aims to examine the evolution of terminology, diagnostic criteria, epidemiologic considerations, and clinical implications of the change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated fatty liver disease (MAFLD) and metabolic dysfunction–associated steatotic liver disease (MASLD).
Rinella, M. E., et al. (2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Journal of Hepatology 79(6): 1542-1556: https://www.sciencedirect.com/science/article/pii/S016882782300418X
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.
Rinella, M. E. and S. Sookoian (2024). "From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease." Journal of Lipid Research 65(1): https://doi.org/10.1016/j.jlr.2023.100485 FULL TEXT AT URL.
Bae, J. C. (2024). "No More NAFLD: The Term Is Now MASLD." enm 39(1): 92-94: http://dx.doi.org/10.3803/EnM.2024.103
http://www.e-sciencecentral.org/articles/?scid=1516086436
PDF AT URL.
Chen, L., et al. (2024). "Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD." Journal of Hepatology 80(2): e64-e66: https://doi.org/10.1016/j.jhep.2023.08.021
PDF AT URL.
He, L., et al. (2024). "Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes." Journal of Hepatology 80(2): e85-e87: https://doi.org/10.1016/j.jhep.2023.09.035
PDF AT LINK.
Lu, Z., et al. (2024). "The transition from NAFLD to MASLD and its impact on clinical practice and outcomes." Journal of Hepatology 81(4): e155-e156: https://doi.org/10.1016/j.jhep.2024.02.021
FULL TEXT AT URL.
Perazzo, H., et al. (2024). "Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort." Journal of Hepatology 80(2): e72-e74: https://doi.org/10.1016/j.jhep.2023.08.025
PDF AT LIMK.
Ramírez-Mejía, M. M. and N. Méndez-Sánchez (2023). "What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications." Current Hepatology Reports 22(4): 221-227: https://doi.org/10.1007/s11901-023-00620-9
PDF AT LINK.
This review aims to examine the evolution of terminology, diagnostic criteria, epidemiologic considerations, and clinical implications of the change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated fatty liver disease (MAFLD) and metabolic dysfunction–associated steatotic liver disease (MASLD).
Rinella, M. E., et al. (2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Journal of Hepatology 79(6): 1542-1556: https://www.sciencedirect.com/science/article/pii/S016882782300418X
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.
Rinella, M. E. and S. Sookoian (2024). "From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease." Journal of Lipid Research 65(1): https://doi.org/10.1016/j.jlr.2023.100485
FULL TEXT AT URL.
E-books are available via the CLIN Libraries' myAthens platform. You will need an account to access these books. Join here.
American Journal of Gastroenterology
01/2000 - Current
Access via CIAP
Clinical and Translational Gastroenterology
01/2010 – Current
Access via CIAP
01/2006 – Current
Full text access available only for Bankstown Hospital staff logging with an OpenAthens account